Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies

Gut microbiome and cancer immunotherapy

(2019) Weina Li et al.   CANCER LETTERS

Butyrate suppresses demyelination and enhances remyelination

(2019) Tong Chen et al.   Journal of Neuroinflammation

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome

(2018) H. Arias-Pulido et al.   BREAST CANCER RESEARCH AND TREATMENT

Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab

(2018) Lucia Y. Chen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance

(2018) Zhenqing Ye et al.   CLINICAL CANCER RESEARCH

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis

(2018) Robert Hermann et al.   CLINICAL PHARMACOKINETICS

Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma

(2018) Ruixia Huang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells

(2018) João Crispim Encarnação et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

(2018) Fabio Conforti et al.   LANCET ONCOLOGY

The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives

(2018) Andrea Huwiler et al.   PHARMACOLOGY & THERAPEUTICS

Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells

(2018) Nathaniel Edward Bennett Saidu et al.   Oncotarget

The Evolving Mechanisms of Action of Glatiramer Acetate

(2018) Thomas Prod'homme et al.   Cold Spring Harbor Perspectives in Medicine

Interferon β for Multiple Sclerosis

(2018) Dejan Jakimovski et al.   Cold Spring Harbor Perspectives in Medicine

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis

(2018) Elizabeth A. Mills et al.   Frontiers in Neurology

Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs

(2018) Christine Lebrun et al.   CNS DRUGS

Short-chain fatty acids and gut microbiota in multiple sclerosis

(2018) Pernille Melbye et al.   ACTA NEUROLOGICA SCANDINAVICA

The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia

(2018) David B. Sykes   EXPERT OPINION ON THERAPEUTIC TARGETS

Multiple sclerosis and cancer incidence: A Danish nationwide cohort study

(2018) M. Nørgaard et al.   Multiple Sclerosis and Related Disorders

FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model

(2017) Agata Szymiczek et al.   Journal of Translational Medicine

Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications

(2017) Nathaniel Edward Bennett Saidu et al.   MOLECULAR CANCER THERAPEUTICS

Anticancer effects of the microbiome and its products

(2017) Laurence Zitvogel et al.   NATURE REVIEWS MICROBIOLOGY

Alemtuzumab CARE-MS I 5-year follow-up

(2017) Eva Havrdova et al.   NEUROLOGY

Alemtuzumab CARE-MS II 5-year follow-up

(2017) Alasdair J. Coles et al.   NEUROLOGY

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correction for Cekanaviciute et al., Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models

(2017)   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice

(2017) Kerstin Berer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

(2017) David Baker et al.   JAMA Neurology

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)

(2017) Rachel A. Sabol et al.   Cancer Medicine

A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis

(2017) Anne Landais et al.   Multiple Sclerosis and Related Disorders

Modulation of Multiple Sclerosis and Its Animal Model Experimental Autoimmune Encephalomyelitis by Food and Gut Microbiota

(2017) Ward J. van den Hoogen et al.   Frontiers in Immunology

Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study

(2017) Xavier Moisset et al.   PLoS One

Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity

(2016) Melanie Schirmer et al.   CELL

An Association Between Glatiramer Acetate and Malignant Melanoma

(2016) John Walker et al.   JOURNAL OF IMMUNOTHERAPY

Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk

(2016) Deeya Gaindh et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Breaking down the gut microbiome composition in multiple sclerosis

(2016) Adrian Budhram et al.   Multiple Sclerosis Journal

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients

(2016) Mohammadhossein Hajiebrahimi et al.   PLoS One

Dimethylfumarate inhibits melanoma cell proliferation via p21 and p53 induction and bcl-2 and cyclin B1 downregulation

(2016) Irina Kaluzki et al.   TUMOR BIOLOGY

The emerging role of FTY720 (Fingolimod) in cancer treatment

(2016) Christopher White et al.   Oncotarget

Breaking down the gut microbiome composition in multiple sclerosis

(2016) Adrian Budhram et al.   Multiple Sclerosis Journal

Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort

(2016) Anja Thormann et al.   Multiple Sclerosis and Related Disorders

B cell regulation of the anti-tumor response and role in carcinogenesis

(2016) Marc Schwartz et al.   Journal for ImmunoTherapy of Cancer

Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway

(2015) Xin Xie et al.   BRITISH JOURNAL OF PHARMACOLOGY

Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein

(2015) Irida Kastrati et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Gut Microbiota in Multiple Sclerosis

(2015) Brandi L. Cantarel et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment

(2015) Nosratola D. Vaziri et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Teriflunomide (Leflunomide) Promotes Cytostatic, Antioxidant, and Apoptotic Effects in Transformed Prostate Epithelial Cells: Evidence Supporting a Role for Teriflunomide in Prostate Cancer Chemoprevention

(2015) Numsen Hail et al.   NEOPLASIA

Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news?

(2014) Craig W. Freyer et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma

(2014) D. J. Inwards et al.   ANNALS OF ONCOLOGY

Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia

(2014) Edouard Cornet et al.   BRITISH JOURNAL OF HAEMATOLOGY

Regulation of dimethyl-fumarate toxicity by proteasome inhibitors

(2014) Laurence Booth et al.   CANCER BIOLOGY & THERAPY

Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

(2014) J. R. Brown et al.   CLINICAL CANCER RESEARCH

Featured Article: Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells

(2014) Ou Huang et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

How Type I Interferons Work in Multiple Sclerosis and Other Diseases: Some Unexpected Mechanisms

(2014) Anthony T. Reder et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Assessment of cancer risk with β-interferon treatment for multiple sclerosis

(2014) Elaine Kingwell et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential

(2014) I. Cristobal et al.   MOLECULAR CANCER THERAPEUTICS

Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies

(2014) Ferrán Catalá-López et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway

(2014) Li Zhang et al.   TUMOR BIOLOGY

Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series

(2013) J. D. Rosenberg et al.   BLOOD

Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L

(2013) M. Bodogai et al.   CANCER RESEARCH

Inhibition of the type I immune responses of human monocytes by IFN-α and IFN-β

(2013) Roelof A. de Paus et al.   CYTOKINE

Immunomodulatory Effects of Interferons in Malignancies

(2013) Joseph Bekisz et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

FTY720 for cancer therapy (Review)

(2013) LI ZHANG et al.   ONCOLOGY REPORTS

Pathogenic Intestinal Bacteria Enhance Prostate Cancer Development via Systemic Activation of Immune Cells in Mice

(2013) Theofilos Poutahidis et al.   PLoS One

New insights into the synergism of nucleoside analogs with radiotherapy

(2013) Michael W Lee et al.   Radiation Oncology

Regulatory T Cells and Immune Tolerance in the Intestine

(2013) O. J. Harrison et al.   Cold Spring Harbor Perspectives in Biology

Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response

(2013) Giovanna Schiavoni et al.   Frontiers in Immunology

Cancer risk in multiple sclerosis: findings from British Columbia, Canada

(2012) Elaine Kingwell et al.   BRAIN

Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

(2012) R. Rosa et al.   CLINICAL CANCER RESEARCH

CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer

(2012) J. S. Nielsen et al.   CLINICAL CANCER RESEARCH

A gender-related action of IFNbeta-therapy was found in multiple sclerosis

(2012) Ida Contasta et al.   Journal of Translational Medicine

Type I Interferons Induce Apoptosis by Balancing cFLIP and Caspase-8 Independent of Death Ligands

(2012) A. Apelbaum et al.   MOLECULAR AND CELLULAR BIOLOGY

Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma

(2012) A. Estrada-Bernal et al.   NEURO-ONCOLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study)

(2012) Melinda Magyari et al.   Multiple Sclerosis and Related Disorders

Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells

(2011) S. Dietrich et al.   CLINICAL CANCER RESEARCH

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

(2011) Hany A. Omar et al.   HEPATOLOGY

FTY720 Analogues as Sphingosine Kinase 1 Inhibitors

(2011) Keng G. Lim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fingolimod modulates microglial activation to augment markers of remyelination

(2011) Samuel J Jackson et al.   Journal of Neuroinflammation

Cancer and multiple sclerosis in the era of disease-modifying treatments

(2011) Christine Lebrun et al.   JOURNAL OF NEUROLOGY

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

DHODH modulates transcriptional elongation in the neural crest and melanoma

(2011) Richard Mark White et al.   NATURE

Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination

(2011) Kerstin Berer et al.   NATURE

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple sclerosis and cancer in Norway A retrospective cohort study

(2010) R. Midgard et al.   ACTA NEUROLOGICA SCANDINAVICA

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

(2010) F. Morschhauser et al.   ANNALS OF ONCOLOGY

FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: A protective role of autophagy

(2010) Ning Zhang et al.   Autophagy

Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers

(2010) K. G. Roberts et al.   CANCER RESEARCH

FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells

(2010) Francesca Tonelli et al.   CELLULAR SIGNALLING

FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma

(2010) Q. Liu et al.   CLINICAL CANCER RESEARCH

Glatiramer Acetate

(2010) Natalie J. Carter et al.   DRUGS

Regulatory T cells in tumor immunity

(2010) Hiroyoshi Nishikawa et al.   INTERNATIONAL JOURNAL OF CANCER

PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice

(2010) Tongsen Zheng et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

APC Activation by IFN-  Decreases Regulatory T Cell and Enhances Th Cell Functions

(2010) L. Pace et al.   JOURNAL OF IMMUNOLOGY

Interferon-β induces apoptosis in human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/Akt pathway

(2010) Simona Dedoni et al.   JOURNAL OF NEUROCHEMISTRY

Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth

(2010) M. R. Cook et al.   MOLECULAR CANCER THERAPEUTICS

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia

(2009) Hiroto Inaba et al.   CANCER

Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells

(2009) Yuzuru Yamazoe et al.   CELL BIOLOGY INTERNATIONAL

Risk of additional cancers in untreated and treated hairy cell leukemia patients

(2009) Constantin A Dasanu et al.   EXPERT OPINION ON PHARMACOTHERAPY

FTY720 and lung tumor development

(2009) Natália Regina Antunes Salinas et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The Sphingosine 1-Phosphate Receptor Agonist FTY720 Potently Inhibits Regulatory T Cell Proliferation In Vitro and In Vivo

(2009) A. M. Wolf et al.   JOURNAL OF IMMUNOLOGY

Combination of Dacarbazine and Dimethylfumarate Efficiently Reduces Melanoma Lymph Node Metastasis

(2009) Teresa Valero et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies

(2009) A. F Fois et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells

(2009) P. Baumann et al.   MOLECULAR CANCER THERAPEUTICS

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

(2009) G. Comi et al.   Multiple Sclerosis Journal

Interferon-  mechanisms of action in multiple sclerosis

(2009) S. Dhib-Jalbut et al.   NEUROLOGY

Cancer risk among patients with multiple sclerosis and their parents

(2009) S. Bahmanyar et al.   NEUROLOGY

Lung Tumor Development in the Presence of Sphingosine 1-phosphate Agonist FTY720

(2009) Natália R. Salinas et al.   PATHOLOGY & ONCOLOGY RESEARCH

Glatiramer Acetate–Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma

(2008) Monica M. Madray et al.   ARCHIVES OF NEUROLOGY

Effects of Phosphorylation of Immunomodulatory Agent FTY720 (Fingolimod) on Antiproliferative Activity against Breast and Colon Cancer Cells

(2008) Yasuo Nagaoka et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C   Signaling

(2008) J.-H. Hung et al.   CANCER RESEARCH

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

(2008) M. Schmidt et al.   CANCER RESEARCH

Downregulating sphingosine kinase-1 for cancer therapy

(2008) Olivier Cuvillier   EXPERT OPINION ON THERAPEUTIC TARGETS

Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis

(2008) Christine Lebrun et al.   Multiple Sclerosis Journal

Immunosuppressive therapy and post-transplant malignancy

(2008) S. Domhan et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

(2008) S. Demko et al.   ONCOLOGIST

Antiproliferative and Overadditive Effects of Rapamycin and FTY720 in Pancreatic Cancer Cells In Vitro

(2008) Y. Shen et al.   TRANSPLANTATION PROCEEDINGS